Literature DB >> 9264380

Multiparameter phenotype mapping of normal and post-chemotherapy B lymphopoiesis in pediatric bone marrow.

M N Dworzak1, G Fritsch, C Fleischer, D Printz, G Fröschl, P Buchinger, G Mann, H Gadner.   

Abstract

We studied the differentiation profiles of B cell precursors (BCP) in normal and post-chemotherapy pediatric bone marrow (BM) using multiparameter flow cytometry. The goal of our study was to draw a comprehensive phenotypic map of the three major maturational BCP stages in BM. By correlating lineage-associated markers, CD45RA, and several adhesion molecules, the stage-specific patterns were found to differ in certain details from previously published concepts. Among the earliest BCP, a subset of CD34+ CD10(lo) precursors was repeatedly observed in addition to the well characterized CD34+ CD10(hi) CD19+ majority of cells. Only two-thirds of these CD34+ CD10(lo) cells expressed CD19. However, uniformity of phenotypic features, absence of T lineage markers, and the regeneration kinetics after chemotherapy suggest the B lineage affiliation of the CD34+ CD10(lo) precursors in general. In the more mature BCP, expression of CD10, CD20, cytoplasmic and surface mu chains (c mu and s mu) was observed to overlap more than previously recognized. We found that CD20 and c mu appear early during B cell ontogeny (already on CD34+ BCP), and that CD10 is lost late, following the onset of s mu expression. Differences between normal and post-chemotherapy BM specimens regarding the phenotypic appearance of BCP were exclusively due to differences in the subset composition, as post-chemotherapy samples showed a preponderance of immature stages. Our observations may build a framework for comparing leukemic cells with their normal counterparts to define possible leukemia-associated aberrations useful for residual disease studies.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9264380     DOI: 10.1038/sj.leu.2400732

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  7 in total

1.  Time point-dependent concordance of flow cytometry and real-time quantitative polymerase chain reaction for minimal residual disease detection in childhood acute lymphoblastic leukemia.

Authors:  Giuseppe Gaipa; Giovanni Cazzaniga; Maria Grazia Valsecchi; Renate Panzer-Grümayer; Barbara Buldini; Daniela Silvestri; Leonid Karawajew; Oscar Maglia; Richard Ratei; Alessandra Benetello; Simona Sala; Angela Schumich; Andre Schrauder; Tiziana Villa; Marinella Veltroni; Wolf-Dieter Ludwig; Valentino Conter; Martin Schrappe; Andrea Biondi; Michael N Dworzak; Giuseppe Basso
Journal:  Haematologica       Date:  2012-05-11       Impact factor: 9.941

2.  Minimal residual disease analysis by eight-color flow cytometry in relapsed childhood acute lymphoblastic leukemia.

Authors:  Leonid Karawajew; Michael Dworzak; Richard Ratei; Peter Rhein; Giuseppe Gaipa; Barbara Buldini; Giuseppe Basso; Ondrej Hrusak; Wolf-Dieter Ludwig; Günter Henze; Karl Seeger; Arend von Stackelberg; Ester Mejstrikova; Cornelia Eckert
Journal:  Haematologica       Date:  2015-05-22       Impact factor: 9.941

3.  CD20 up-regulation in pediatric B-cell precursor acute lymphoblastic leukemia during induction treatment: setting the stage for anti-CD20 directed immunotherapy.

Authors:  Michael N Dworzak; Angela Schumich; Dieter Printz; Ulrike Pötschger; Zvenyslava Husak; Andishe Attarbaschi; Giuseppe Basso; Giuseppe Gaipa; Richard Ratei; Georg Mann; Helmut Gadner
Journal:  Blood       Date:  2008-09-09       Impact factor: 22.113

Review 4.  Minimal residual disease in acute lymphoblastic leukemia: optimal methods and clinical relevance, pitfalls and recent approaches.

Authors:  Fatemeh Salari; Mohammad Shahjahani; Saeid Shahrabi; Najmaldin Saki
Journal:  Med Oncol       Date:  2014-10-07       Impact factor: 3.064

Review 5.  Current Strategies for the Detection of Minimal Residual Disease in Childhood Acute Lymphoblastic Leukemia.

Authors:  Juliana Maria Camargos Rocha; Sandra Guerra Xavier; Marcelo Eduardo de Lima Souza; Juliana Godoy Assumpção; Mitiko Murao; Benigna Maria de Oliveira
Journal:  Mediterr J Hematol Infect Dis       Date:  2016-04-10       Impact factor: 2.576

6.  An Extensive Quality Control and Quality Assurance (QC/QA) Program Significantly Improves Inter-Laboratory Concordance Rates of Flow-Cytometric Minimal Residual Disease Assessment in Acute Lymphoblastic Leukemia: An I-BFM-FLOW-Network Report.

Authors:  Margarita Maurer-Granofszky; Angela Schumich; Barbara Buldini; Giuseppe Gaipa; Janos Kappelmayer; Ester Mejstrikova; Leonid Karawajew; Jorge Rossi; Adın Çınar Suzan; Evangelina Agriello; Theodora Anastasiou-Grenzelia; Virna Barcala; Gábor Barna; Drago Batinić; Jean-Pierre Bourquin; Monika Brüggemann; Karolina Bukowska-Strakova; Hasan Burnusuzov; Daniela Carelli; Günnur Deniz; Klara Dubravčić; Tamar Feuerstein; Marie Isabel Gaillard; Adriana Galeano; Hugo Giordano; Alejandro Gonzalez; Stefanie Groeneveld-Krentz; Zsuzsanna Hevessy; Ondrej Hrusak; Maria Belen Iarossi; Pál Jáksó; Veronika Kloboves Prevodnik; Saskia Kohlscheen; Elena Kreminska; Oscar Maglia; Cecilia Malusardi; Neda Marinov; Bibiana Maria Martin; Claudia Möller; Sergey Nikulshin; Jorge Palazzi; Georgios Paterakis; Alexander Popov; Richard Ratei; Cecilia Rodríguez; Elisa Olga Sajaroff; Simona Sala; Gordana Samardzija; Mary Sartor; Pamela Scarparo; Łukasz Sędek; Bojana Slavkovic; Liliana Solari; Peter Svec; Tomasz Szczepanski; Anna Taparkou; Montserrat Torrebadell; Marianna Tzanoudaki; Elena Varotto; Helly Vernitsky; Andishe Attarbaschi; Martin Schrappe; Valentino Conter; Andrea Biondi; Marisa Felice; Myriam Campbell; Csongor Kiss; Giuseppe Basso; Michael N Dworzak
Journal:  Cancers (Basel)       Date:  2021-12-06       Impact factor: 6.639

7.  Proposal for the standardization of flow cytometry protocols to detect minimal residual disease in acute lymphoblastic leukemia.

Authors:  Maura Rosane Valério Ikoma; Miriam Perlingeiro Beltrame; Silvia Inês Alejandra Cordoba Pires Ferreira; Elizabeth Xisto Souto; Mariester Malvezzi; Mihoko Yamamoto
Journal:  Rev Bras Hematol Hemoter       Date:  2015-09-28
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.